Evaluation of Anti-GD2 Antibody-Drug Conjugate M3554 in Patients with Advanced Solid Tumors

The primary objective of the study titled "Anti-GD2 ADC M3554 in Advanced Solid Tumors" is to evaluate the efficacy and safety of the investigational drug **Anti-GD2 ADC M3554** in patients with **advanced solid tumors**. This is clinically relevant as advanced solid tumors often present significant treatment challenges, and new therapeutic options are needed to improve patient outcomes. The study aims to determine the potential of this targeted therapy to provide clinical benefits in terms of tumor response and patient survival. No secondary objectives are provided in the available data.

The clinical trial involves a total of **26 participants** diagnosed with **Advanced Solid Tumors**. The study population includes both male and female subjects, with an age range encompassing adults and older adults. Participants were selected to include a vulnerable population, although specific criteria for vulnerability are not detailed. The trial does not specify particular lifestyle considerations such as diet, physical activity, or habits. The sponsor has not provided detailed information regarding the main objective of the trial or the principal inclusion criteria. The health status of participants is characterized by the presence of advanced solid tumors, indicating a focus on individuals with significant oncological conditions.

The clinical trial is designed to evaluate the safety and efficacy of a novel therapeutic agent in patients with **advanced solid tumors**. This study is structured as a Phase 1 trial, which is typically the initial phase in clinical research aimed at assessing the safety profile of a new treatment. The trial employs a randomized, double-blind, and controlled design to ensure the reliability and validity of the results. The estimated duration of the trial is from December 31, 2024, to September 20, 2026, encompassing both the recruitment and follow-up periods.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit. During this visit, eligibility criteria will be assessed to confirm the participant's suitability for the trial. Following successful inclusion, participants will attend regular follow-up visits, which are scheduled to monitor the treatment's effects and any adverse events. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The trial will conclude with an end-of-study visit, where final assessments will be conducted to evaluate the overall outcomes of the treatment.

The expected length of participant involvement in the trial is approximately 21 months, depending on the individual's response to the treatment and the occurrence of any adverse events. Participants may be subject to early termination from the study if they experience significant adverse reactions, fail to comply with the study protocol, or withdraw consent. The trial's design and procedures are meticulously planned to ensure the safety and well-being of participants while providing valuable data on the investigational treatment's potential benefits and risks.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available. Additionally, details about drug administration, dosing schedules, and participant compliance monitoring are not included in the source data. Consequently, no further information can be offered regarding the substances used in this study.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is December 31, 2024, with an anticipated end date of September 20, 2026. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy through various measures. These may include symptom improvement scores, biomarker levels, or other relevant clinical indicators, depending on the investigational product and the condition being studied. The methods for measuring and analyzing these parameters are typically aligned with standard clinical practices, utilizing validated scales or laboratory tests at predetermined timepoints throughout the trial duration. The data collected will be analyzed to determine the initial efficacy profile of the investigational product, providing foundational insights for subsequent trial phases.